(EVAX) Evaxion Biotech A/S Business Model Canvas Research

Evaxion Biotech A/S uses academic and scientific collaborators to add oncology, immunology, and infectious-disease expertise it does not keep in-house, and that input helps sharpen target selection, assay design, and translational science. These ties also strengthen validation of AI-generated candidates before clinical work.

• External experts de-risk target choice
• Academic labs improve assay quality
• Validation boosts candidate credibility

Evaxion Biotech A/S depends on non-dilutive funding and equity markets to keep R&D moving, so grant makers, lenders, and investors are core partners. Regulators in Europe and other markets also shape trial design, compliance, and the evidence needed for later commercialization.

• Funding supports R&D runway
• Regulators guide trial setup
• Compliance drives market access

AI-supported biomarker and patient-stratification work helps Evaxion Biotech A/S match therapies to the patients most likely to respond, which matters in melanoma where anti-PD-1 response rates are often only about 40% to 50%. Better selection can lift clinical hit rates, cut trial waste, and speed readouts in immuno-oncology studies.

• Match therapy to responders
• Improve melanoma trial efficiency
• Reduce non-responder exposure
• Support faster go/no-go decisions

Evaxion Biotech A/S must keep regulatory filings, CMC controls, and patent coverage tight because these are the gatekeepers for trial approvals and future partner due diligence. For a biotech with no product sales, these functions are core value drivers, not back-office work.

They reduce delays, protect data and know-how, and help keep the platform investable.

• Regulatory filings support trial starts
• CMC ensures batch quality and consistency
• IP protects partnering value

Evaxion Biotech A/S depends on a scientific and technical team in immunology, data science, and clinical development to turn AI outputs into drug candidates. That human layer is key for study design, partner work, and moving programs through development.

• Immunology and AI skills
• Clinical study design
• External collaboration management

Evaxion Biotech A/S relies on patents, AI-driven algorithms, and proprietary datasets to protect its discovery engine and keep control of value created in early research. That IP makes the Company more attractive to partners and helps support future licensing, milestone, and royalty income from partnered programs.

• Patents protect core discovery assets
• Algorithms improve target selection
• Datasets are hard to copy
• IP helps win partner deals
• Licensing can extend value beyond R&D

Evaxion Biotech A/S’s pipeline beyond oncology adds 3 preclinical vaccine candidates for bacterial and viral diseases, broadening its addressable market and reducing dependence on one therapeutic area. That mix can lower scientific concentration risk while creating more partnering paths across infectious disease markets.

• 3 preclinical candidates
• Bacterial and viral disease focus
• Broader market reach

AI-guided selection can reduce the number of weak candidates entering wet-lab development, so Evaxion Biotech A/S can spend capital on fewer dead ends. In drug discovery, only about 1 in 10,000 screened compounds reaches market, so partners get a tighter innovation engine and a lower cost per asset over time.

• Fewer failed candidates
• Lower development spend
• Better partner efficiency

As a listed biotech, Evaxion Biotech A/S uses investor communications to keep shareholders aligned on trial progress, financing needs, and partnership deals. Transparent updates on clinical milestones and capital raises are the main trust channel, because biotech value can shift fast on one data readout.

• Trial updates move trust fast
• Financing news shapes runway
• Partnerships signal external validation

Evaxion Biotech A/S runs partner ties through clear development milestones, so each step in data generation and go/no-go work has an owner and a date. That model fits biotech deal logic: Evaxion said its MSD collaboration could bring up to USD 39 million in milestone and other payments, which also leaves room for later expansion or licensing.

• Clear milestones, clear accountability
• Forces data-driven decisions
• Supports follow-on deal value

Evaxion Biotech A/S uses its corporate website and press releases to publish trial updates, milestones, and partnership news, giving investors and other stakeholders fast access to key events at very low cost. This channel also supports investor relations and keeps the brand visible without heavy media spend.

• Trial results and pipeline updates
• Partnership and licensing news
• Low-cost investor communication

As a Nasdaq-listed public company, Evaxion Biotech A/S uses market disclosures and investor presentations to turn clinical milestones into funding access for its development pipeline. This channel matters because development-stage biotech needs repeated capital raises, so each data update can shape investor demand.

• Public filings support financing access
• Clinical progress can move valuation
• Investor updates reduce funding friction

Evaxion Biotech A/S can sell to vaccine-focused biotech and pharma partners for its infectious-disease pipeline, not just oncology. These buyers often want platform licensing or co-development, and Evaxion’s partnership model helps widen its reach into adjacent vaccine markets without funding all development alone.

• Targets vaccine-focused biotech and pharma
• Fits licensing or co-development deals
• Expands beyond oncology into infections

Public-market investors are a core economic customer for Evaxion Biotech A/S because their capital funds R&D runway, pipeline progress, and day-to-day operating continuity. They are not end users, but they decide whether the company can keep advancing programs through each clinical and regulatory milestone.

• Provide equity funding for R&D

• Support pipeline advancement

• Keep operations funded

Evaxion Biotech A/S must keep paying for filings, outside counsel, and patent maintenance across all programs, and these fixed costs help protect IP and keep trials moving. In the 2025 annual report, these legal and IP items sat inside ongoing G&A spend, so they scale with pipeline breadth, not just one asset.

• Protects patent rights
• Supports trial filings
• Runs across all programs

Evaxion Biotech A/S keeps public-company and general administration lean, but still pays Nasdaq compliance, finance, and investor relations costs, plus HQ overhead in Hørsholm, Denmark. These costs stay below R&D, yet they remain material because they cover listing duties, reporting, and core corporate running costs.

• Nasdaq compliance and reporting

• Finance and investor relations

• Hørsholm headquarters overhead

• Lower than R&D, still material

Grants and other non-dilutive support can fund early vaccine and infectious disease R&D without new shares, which helps Evaxion Biotech A/S stretch runway. In biotech, this matters because cash burn often rises before any product revenue; public and institutional money can bridge that gap.

• Extends runway without equity dilution
• Fits early-stage vaccine work best
• Supports cash while data matures

Evaxion Biotech A/S can earn license fees and royalties if partners commercialize its candidates, and that is the long-term upside of the model. In its latest public filings, the Company still had no meaningful royalty base, so this is the most scalable revenue stream only if programs succeed.

• Partner commercialization drives future cash.
• License fees can arrive upfront.
• Royalties can scale with sales.
• Current royalty income is not material.